Hawkes Clare, Chandran Jonathan J, Kozlowska Kasia
School of Psychological Sciences, University of Tasmania, Launceston, Australia.
The Department of Adolescent and Young Adult Medicine, Westmead Hospital, Sydney, Australia.
Case Rep Pediatr. 2025 Apr 1;2025:6639748. doi: 10.1155/crpe/6639748. eCollection 2025.
Prucalopride is a highly selective, 5-HT4 receptor agonist that can be used for the treatment of chronic constipation in individuals for whom laxatives fail to provide adequate relief. The current case study describes adverse neuropsychiatric symptoms following the administration of prucalopride in a 15-year-old female with a complex physical and mental health history to manage chronic constipation. A single 2 mg dose of prucalopride was prescribed to a 15-year-old female to manage her chronic constipation due to a diagnosis of autoimmune enteric neuropathy. Following the oral administration of prucalopride, the patient started experiencing visual and auditory hallucinations, along with suicidal ideation. Prucalopride was ceased, with the patient receiving psychopharmacology and psychological intervention to address the acute onset psychiatric symptoms. To our knowledge, this is the second documented case of acute onset neuropsychiatric symptoms following the administration of prucalopride. Clinicians should be aware of this possible side effect, particularly if considering administering prucalopride in patients with neurodevelopmental and psychiatric comorbid histories. Increased supervision and monitoring is recommended in these patients if prucalopride is administrated.
普芦卡必利是一种高选择性的5 - HT4受体激动剂,可用于治疗泻药无法充分缓解便秘的慢性便秘患者。本病例研究描述了一名有复杂身心健康史的15岁女性在服用普芦卡必利治疗慢性便秘后出现的不良神经精神症状。一名15岁女性因自身免疫性肠神经病被诊断为慢性便秘,开具了单剂量2毫克的普芦卡必利。口服普芦卡必利后,患者开始出现视幻觉和听幻觉以及自杀念头。停用了普芦卡必利,患者接受了精神药理学和心理干预以处理急性发作的精神症状。据我们所知,这是第二例记录在案的服用普芦卡必利后急性发作神经精神症状的病例。临床医生应意识到这种可能的副作用,特别是在考虑给有神经发育和精神共病病史的患者使用普芦卡必利时。如果给这些患者使用普芦卡必利,建议加强监督和监测。